Cover Image
Market Research Report
Product code 
1057921

Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026

Published: | MarketsandMarkets | 332 Pages | Delivery time: 1-2 business days

Price

Back to Top
Companion Diagnostics Market by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Region - Global Forecast to 2026
Published: February 8, 2022
MarketsandMarkets
Content info: 332 Pages
Delivery time: 1-2 business days
  • Description
  • Table of Contents

The global companion diagnostics market is projected to reach USD 9.9 billion by 2026 from USD 5.5 billion in 2021, at a CAGR of 12.6% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies.

"The assays, kits & reagents segment accounted for the highest growth rate in the companion diagnostics market, by product & service, during the forecast period."

Based on product & service, the companion diagnostics market is segmented into assays, kits & reagents, and software & services. In 2020, assays, kits & reagents accounted for the largest share of the companion diagnostics market due to the availability of a wide range of products, increasing use of assays and kits in different therapeutic areas, and the growing demand for assays and kits in basic research and commercial applications.

" Pharmaceutical & biotechnology companies segment accounted for the highest CAGR."

Based on end user, the companion diagnostics market is segmented into pharmaceutical & biotechnology companies, reference laboratories, CROs, and other end users. In 2020, pharmaceutical & biotechnology companies were the largest end users of companion diagnostics. This can primarily be attributed to the growing use of companion diagnostics owing to their increasing prominence in drug development and the increasing importance of companion diagnostic biomarkers. The rising demand for personalized medicine, as well as the high need for targeted therapies for various diseases and disorders, are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biotechnology companies.

" North America is the largest regional market for companion diagnostics market."

The global companion diagnostics market has been segmented into five major regions-North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for companion diagnostics. The large share of North America in this market can be attributed to the presence of many leading companion diagnostics vendors & national clinical laboratories, the easy accessibility to technologically advanced devices and instruments, and the highly developed healthcare system in the US and Canada.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6% , and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Qiagen N.V. (Germany), Thermo Fisher Scientific, Inc. (US), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina Inc. (US), bioMerieux SA (France), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), ICON Plc (Ireland), BioGenex Laboratories, Inc. (US), Invivoscribe Technologies (US), ArcherDX, Inc. (US), NG Biotech (France), Q² Solutions (US), Amoy Diagnostics Co., Ltd. (China), Abacus Diagnostica Oy (Finland), Asuragen Inc. (US), SAGA Diagnostics (Sweden), Meso Scale Diagnostics, LLC. (US), and Creative Biolabs (US).

Research Coverage:

This report provides a detailed picture of the companion diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, technology, indication, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall companion diagnostics and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Product Code: MD 5463

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
  • 1.3 MARKETS COVERED
    • FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION
    • 1.3.1 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 COMPANION DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 COMPANION DIAGNOSTICS MARKET: BOTTOM-UP APPROACH
      • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.2.1.3 Growth forecast (2021-2026)
      • 2.2.1.4 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.2.2 TOP-DOWN APPROACH
    • FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 ASSUMPTIONS FOR THE STUDY
  • 2.6 LIMITATIONS
  • 2.7 RISK ASSESSMENT
    • 2.7.1 RISK ASSESSMENT: COMPANION DIAGNOSTICS MARKET
  • 2.8 GROWTH RATE ASSUMPTIONS
  • 2.9 COVID-19 HEALTH ASSESSMENT
  • 2.10 COVID-19 ECONOMIC ASSESSMENT
  • 2.11 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO
    • FIGURE 8 CRITERIA IMPACTING GLOBAL ECONOMY
    • FIGURE 9 RECOVERY SCENARIO OF GLOBAL ECONOMY
  • 2.12 ASSESSMENT OF IMPACT OF COVID-19 ON ECONOMIC SCENARIO IN COMPANION DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 14 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 COMPANION DIAGNOSTICS MARKET OVERVIEW
    • FIGURE 15 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
  • 4.2 COMPANION DIAGNOSTICS MARKET SHARE, BY PRODUCT & SERVICE, 2021 VS. 2026
    • FIGURE 16 ASSAYS, KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2026
  • 4.3 COMPANION DIAGNOSTICS MARKET SHARE, BY TECHNOLOGY, 2021 VS. 2026
    • FIGURE 17 POLYMERASE CHAN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • 4.4 COMPANION DIAGNOSTICS MARKET SHARE, BY INDICATION, 2021 VS. 2026
    • FIGURE 18 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • 4.5 COMPANION DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
    • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2026
  • 4.6 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Advantages of companion diagnostics
        • 5.2.1.1.1 Growing need for targeted therapy
        • 5.2.1.1.2 Rising importance of personalized medicine
    • FIGURE 22 GLOBAL LAUNCH OF PERSONALIZED MEDICINE PRODUCTS, 2008-2020
    • FIGURE 23 GROWTH IN US FDA PERSONALIZED MEDICINE APPROVAL RATE, 2015-2020
        • 5.2.1.1.3 Increasing global incidence of cancer
    • FIGURE 24 GLOBAL CANCER INCIDENCE, 2008-2030
        • 5.2.1.1.4 Growing application areas of companion diagnostics
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High capital investment and low cost-benefit ratio
      • 5.2.2.2 Expensive companion diagnostic tests
      • 5.2.2.3 Uncertain reimbursement scenario in different regions
    • TABLE 1 COMPANION DIAGNOSTICS REIMBURSEMENT SCENARIO WORLDWIDE
      • 5.2.2.4 High cost of immunotherapy treatment
    • TABLE 2 COST OF KEYTRUDA, BY REGION (2018)
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing demand for next-generation sequencing
    • TABLE 3 PARTNERSHIPS & COLLABORATIONS FOR DEVELOPING NGS-BASED COMPANION DIAGNOSTIC TESTS
      • 5.2.3.2 Growing significance of companion diagnostics in drug development
      • 5.2.3.3 Higher number of clinical trials
    • TABLE 4 LIST OF CLINICAL TRIALS FOR COMPANION DIAGNOSTICS
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of trained professionals
      • 5.2.4.2 Lack of awareness of companion diagnostics testing
  • 5.3 IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
  • 5.4 PESSIMISTIC, OPTIMISTIC, AND REALISTIC SCENARIOS
    • 5.4.1 COMPANION DIAGNOSTICS MARKET
    • FIGURE 25 PESSIMISTIC SCENARIO
    • FIGURE 26 OPTIMISTIC SCENARIO
    • FIGURE 27 REALISTIC SCENARIO
  • 5.5 PRICING ANALYSIS
    • TABLE 5 PRICE OF COMPANION DIAGNOSTICS PRODUCT & SERVICE (2021)
  • 5.6 PATENT ANALYSIS
    • FIGURE 28 PATENT ANALYSIS OF COMPANION DIAGNOSTICS MARKET
  • 5.7 TRADE ANALYSIS
    • 5.7.1 TRADE ANALYSIS FOR COMPANION DIAGNOSTICS
    • TABLE 6 IMPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016-2020 (USD MILLION)
    • TABLE 7 EXPORT DATA FOR COMPANION DIAGNOSTICS, BY COUNTRY, 2016-2020 (USD MILLION)
  • 5.8 VALUE CHAIN ANALYSIS
    • FIGURE 29 MAJOR VALUE IS ADDED DURING MANUFACTURING & ASSEMBLY PHASE
  • 5.9 SUPPLY CHAIN ANALYSIS
    • FIGURE 30 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • 5.10 ECOSYSTEM ANALYSIS OF COMPANION DIAGNOSTICS MARKET
    • FIGURE 31 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
    • 5.10.1 ROLE IN ECOSYSTEM
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 8 COMPANION DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF BUYERS
    • 5.11.4 BARGAINING POWER OF SUPPLIERS
    • 5.11.5 DEGREE OF COMPETITION
  • 5.12 REGULATORY LANDSCAPE
    • 5.12.1 NORTH AMERICA
      • 5.12.1.1 US
      • 5.12.1.2 Canada
    • 5.12.2 EUROPE
    • 5.12.3 ASIA PACIFIC
      • 5.12.3.1 China
      • 5.12.3.2 Japan
      • 5.12.3.3 India
    • 5.12.4 LATIN AMERICA
      • 5.12.4.1 Brazil
      • 5.12.4.2 Mexico
    • 5.12.5 MIDDLE EAST
  • 5.13 TECHNOLOGY ANALYSIS
  • 5.14 PESTLE ANALYSIS
  • 5.15 TRENDS/DISRUPTIONS IMPACTING THE BUSINESS OF CUSTOMERS
    • 5.15.1 REVENUE SOURCES ARE SHIFTING TOWARDS TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19 PANDEMIC
    • 5.15.2 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET

6 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 10 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
  • 6.2 ASSAYS, KITS & REAGENTS
    • 6.2.1 INCREASING VOLUME OF CDX TESTS PERFORMED IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
    • TABLE 11 KEY PRODUCTS IN ASSAYS AND KITS, BY COMPANY
    • TABLE 12 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 13 COMPANION DIAGNOSTIC ASSAYS, KITS& REAGENTS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
  • 6.3 SOFTWARE & SERVICES
    • 6.3.1 NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
    • TABLE 14 KEY PRODUCTS IN SOFTWARE & SERVICES, BY COMPANY
    • TABLE 15 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 16 COMPANION DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY COUNTRY, 2021-2026 (USD MILLION)

7 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
    • TABLE 17 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 18 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
  • 7.2 POLYMERASE CHAIN REACTION (PCR)
    • 7.2.1 GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 19 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
    • TABLE 20 MAJOR PCR TESTS/KITS AVAILABLE
    • TABLE 21 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 22 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2021-2026 (USD MILLION)
  • 7.3 NEXT-GENERATION SEQUENCING
    • 7.3.1 EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
    • TABLE 23 MAJOR NGS TESTS/KITS AVAILABLE
    • TABLE 24 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 25 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2021-2026 (USD MILLION)
  • 7.4 IN SITU HYBRIDIZATION
    • 7.4.1 INCREASING DEMAND IN SMALL-TUMOR DIAGNOSTICS TO DRIVE GROWTH
    • TABLE 26 MAJOR ISH TESTS/KITS AVAILABLE
    • TABLE 27 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 28 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2021-2026 (USD MILLION)
  • 7.5 IMMUNOHISTOCHEMISTRY (IHC)
    • 7.5.1 INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
    • TABLE 29 MAJOR IHC TESTS/KITS AVAILABLE
    • TABLE 30 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 31 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2021-2026 (USD MILLION)
  • 7.6 OTHER TECHNOLOGIES
    • TABLE 32 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 33 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2021-2026 (USD MILLION)

8 COMPANION DIAGNOSTICS MARKET, BY INDICATION

  • 8.1 INTRODUCTION
    • TABLE 34 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 35 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
  • 8.2 CANCER
    • TABLE 36 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 37 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 38 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 39 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
    • 8.2.1 LUNG CANCER
      • 8.2.1.1 Growing demand for effective therapeutic drugs to increase CDX adoption
    • FIGURE 32 GLOBAL LUNG CANCER INCIDENCE, 2012-2030
    • TABLE 40 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 41 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
    • 8.2.2 BREAST CANCER
      • 8.2.2.1 Wide prevalence of breast cancer among women contributes to large size of segment
    • TABLE 42 BREAST CANCER INCIDENCE, BY REGION, 2020 VS. 2030
    • TABLE 43 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 44 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
    • 8.2.3 BLOOD CANCER
      • 8.2.3.1 Increasing incidence of disease to boost market
    • TABLE 45 BLOOD CANCER INCIDENCE, BY REGION, 2020 VS. 2030
    • TABLE 46 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 47 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
    • 8.2.4 COLORECTAL CANCER
      • 8.2.4.1 Rising need for molecular profiling of primary tumors to drive segment growth
    • TABLE 48 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 49 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021-2026 (USD MILLION)
    • 8.2.5 OTHER CANCERS
    • TABLE 50 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 51 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2021-2026 (USD MILLION)
  • 8.3 INFECTIOUS DISEASES
    • 8.3.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH
    • TABLE 52 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 53 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DIESEASES, BY COUNTRY, 2021-2026 (USD MILLION)
  • 8.4 CARDIOVASCULAR DISEASES
    • 8.4.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
    • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 55 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2021-2026 (USD MILLION)
  • 8.5 NEUROLOGICAL DISEASES
    • 8.5.1 GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
    • TABLE 56 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 57 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2021-2026 (USD MILLION)
  • 8.6 OTHER INDICATIONS
    • TABLE 58 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 59 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2026 (USD MILLION)

9 COMPANION DIAGNOSTICS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 60 COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 61 COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 INCREASING USE OF CDX IN PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DRIVE MARKET GROWTH
    • TABLE 62 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 63 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021-2026 (USD MILLION)
  • 9.3 REFERENCE LABORATORIES
    • 9.3.1 RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
    • TABLE 64 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 65 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2021-2026 (USD MILLION)
  • 9.4 CONTRACT RESEARCH ORGANIZATIONS
    • 9.4.1 SIGNIFICANT DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS
    • TABLE 66 COMPANION DIAGNOSTICS MARKET FOR CRO, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 67 COMPANION DIAGNOSTICS MARKET FOR CRO BY COUNTRY, 2021-2026 (USD MILLION)
  • 9.5 OTHER END USERS
    • TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 69 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2021-2026 (USD MILLION)

10 COMPANION DIAGNOSTICS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 70 COMPANION DIAGNOSTICS MARKET, BY REGION, 2017-2020 (USD MILLION)
    • TABLE 71 COMPANION DIAGNOSTICS MARKET, BY REGION, 2021-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • TABLE 72 NUMBER OF NEW CANCER CASES IN NORTH AMERICA IN 2020, BY TYPE OF CANCER
    • FIGURE 33 NORTH AMERICA: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 34 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 73 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
    • TABLE 75 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 76 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 77 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 79 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 81 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 82 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 83 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 84 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Increasing use of companion diagnostics for cancer treatment boosts market
    • TABLE 85 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 86 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 87 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 88 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 89 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 90 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 91 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 92 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 93 US: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 94 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 95 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing government initiatives expected to drive market
    • TABLE 96 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 97 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 98 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 99 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 100 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 101 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 102 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 103 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 104 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 105 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 106 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 35 EUROPE: CANCER INCIDENCE & MORTALITY, 2012-2035
    • TABLE 107 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 108 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
    • TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 110 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 111 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 112 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 113 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 115 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 116 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 117 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 118 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Favorable government policies to drive market
    • TABLE 119 GERMANY: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 120 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 121 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 122 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 123 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 124 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 125 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 126 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 127 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 128 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 129 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Growing life science industry and increasing focus on research to propel market
    • TABLE 130 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 131 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 132 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 133 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 134 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 135 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 136 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 137 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 138 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 139 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.3 SWITZERLAND
      • 10.3.3.1 Strong research-oriented pharma industry supports market growth
    • TABLE 140 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 141 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 142 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 143 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 144 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 145 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 146 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 147 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 148 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 149 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.4 FRANCE
      • 10.3.4.1 Increasing government funding for research to support market growth
    • TABLE 150 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 151 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 152 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 153 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 154 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 155 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 156 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 157 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 158 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 159 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.5 ITALY
      • 10.3.5.1 Growing demand for better and more powerful therapeutics
    • TABLE 160 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 161 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 162 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 163 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 164 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 165 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 166 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 167 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 168 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 169 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing focus on advancement of personalized medicine to drive market growth
    • TABLE 170 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 171 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 172 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 173 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 174 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 175 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 176 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 177 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 178 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 179 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.3.7 REST OF EUROPE
    • TABLE 180 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 181 ROE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 182 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 183 ROE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 184 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 185 ROE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 186 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 187 ROE: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 188 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 189 ROE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 36 ASIA PACIFIC: CANCER INCIDENCE & MORTALITY, 2012-2035
    • FIGURE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
    • TABLE 190 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
    • TABLE 192 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 193 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 194 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 195 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 196 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 197 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 199 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 200 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 201 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Growing public access to advanced healthcare facilities to drive market
    • TABLE 202 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 203 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 204 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 205 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 206 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 207 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 208 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 209 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 210 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 211 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Research initiatives supporting market growth
    • TABLE 212 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 213 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 214 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 215 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 216 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 217 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 218 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 219 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 220 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 221 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 222 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Increased demand for early cancer diagnosis to support market growth
    • TABLE 223 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2020 VS. 2040
    • TABLE 224 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 225 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 226 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 227 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 228 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 229 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 230 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 231 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 232 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 233 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Initiatives to enhance healthcare access and infrastructure for aging population to drive market
    • TABLE 234 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 235 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 236 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 237 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 238 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 239 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 240 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 241 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 242 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 243 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.4.5 REST OF ASIA PACIFIC
    • TABLE 244 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 245 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 246 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 247 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 248 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 249 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 250 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 251 ROAPAC: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 252 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 253 ROAPAC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • TABLE 254 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2017-2020 (USD MILLION)
    • TABLE 255 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2021-2026 (USD MILLION)
    • TABLE 256 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 257 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 258 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 259 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 260 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 261 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 262 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 263 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 264 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 265 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.5.1 BRAZIL
      • 10.5.1.1 Increasing incidence of lifestyle diseases drives market
    • TABLE 266 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 267 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 268 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 269 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 270 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 271 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 272 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 273 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 274 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 275 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.5.2 MEXICO
      • 10.5.2.1 Growing medical tourism to fuel demand for companion diagnostics
    • TABLE 276 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 277 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 278 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 279 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 280 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 281 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 282 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 283 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 284 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 285 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
    • 10.5.3 REST OF LATIN AMERICA
    • TABLE 286 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 287 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 288 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 289 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 290 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 291 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 292 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 293 ROLATAM: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 294 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 295 ROLATAM: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
    • TABLE 296 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2017-2020 (USD MILLION)
    • TABLE 297 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2021-2026 (USD MILLION)
    • TABLE 298 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2017-2020 (USD MILLION)
    • TABLE 299 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2026 (USD MILLION)
    • TABLE 300 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2017-2020 (USD MILLION)
    • TABLE 301 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2021-2026 (USD MILLION)
    • TABLE 302 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2017-2020 (USD MILLION)
    • TABLE 303 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER BY TYPE, 2021-2026 (USD MILLION)
    • TABLE 304 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2017-2020 (USD MILLION)
    • TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2021-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET
    • TABLE 306 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANION DIAGNOSTICS MANUFACTURING COMPANIES
  • 11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 38 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICS MARKET (2015-2020)
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 39 COMPANION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)
    • TABLE 307 COMPANION DIAGNOSTICSMARKET: DEGREE OF COMPETITION
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 LIST OF EVALUATED VENDORS
    • 11.5.2 STARS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PERVASIVE PLAYERS
    • 11.5.5 PARTICIPANTS
    • FIGURE 40 COMPANION DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2020
  • 11.6 COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES (2020)
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 41 COMPANION DIAGNOSTICSMARKET: COMPETITIVE LEADERSHIP MAPPING FOR STARTUPS/SMES, 2020
  • 11.7 COMPETITIVE BENCHMARKING
    • 11.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
    • FIGURE 42 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN COMPANION DIAGNOSTICSMARKET
    • TABLE 308 PRODUCT FOOTPRINT OF COMPANIES
    • TABLE 309 REGIONAL FOOTPRINT OF COMPANIES
  • 11.8 COMPETITIVE SCENARIO
    • 11.8.1 PRODUCT LAUNCHES & REGULATORY APPROVALS
    • TABLE 310 KEY PRODUCT LAUNCHES
    • 11.8.2 DEALS
    • TABLE 311 KEY DEALS

12 COMPANY PROFILES

  • (Business overview, Products offered, Recent developments & MnM View)**
  • 12.1 KEY PLAYERS
    • 12.1.1 F. HOFFMANN-LA ROCHE AG
    • TABLE 312 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 43 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)
    • 12.1.2 AGILENT TECHNOLOGIES, INC.
    • TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
    • FIGURE 44 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.3 QIAGEN
    • TABLE 314 QIAGEN: BUSINESS OVERVIEW
    • FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2020)
    • 12.1.4 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 315 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 46 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.5 ABBOTT LABORATORIES, INC.
    • TABLE 316 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 47 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.6 ALMAC GROUP
    • TABLE 317 ALMAC GROUP: BUSINESS OVERVIEW
    • 12.1.7 DANAHER CORPORATION
    • TABLE 318 DANAHER CORPORATION: BUSINESS OVERVIEW
    • FIGURE 48 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)
    • 12.1.8 ILLUMINA, INC.
    • TABLE 319 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.9 BIOMERIEUX SA
    • TABLE 320 BIOMERIEUX SA: BUSINESS OVERVIEW
    • FIGURE 50 BIOMERIEUX SA: COMPANY SNAPSHOT (2020)
    • 12.1.10 MYRIAD GENETICS, INC.
    • TABLE 321 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
    • FIGURE 51 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2020)
    • 12.1.11 SYSMEX CORPORATION
    • TABLE 322 SYSMEX CORPORATION: BUSINESS OVERVIEW
    • FIGURE 52 SYSMEX CORPORATION: COMPANY SNAPSHOT (2020)
  • *Details on Business overview, Products offered, Recent developments & MnM View might not be captured in case of unlisted companies.
  • 12.2 OTHER PLAYERS
    • 12.2.1 ABNOVA CORPORATION
    • 12.2.2 GUARDANT HEALTH, INC.
    • 12.2.3 ICON PLC
    • 12.2.4 BIOGENEX LABORATORIES, INC.
    • 12.2.5 INVIVOSCRIBE TECHNOLOGIES
    • 12.2.6 ARCHERDX, INC.
    • 12.2.7 NG BIOTECH
    • 12.2.8 Q² SOLUTIONS
    • 12.2.9 AMOY DIAGNOSTICS CO., LTD.
    • 12.2.10 ABACUS DIAGNOSTICA OY
    • 12.2.11 ASURAGEN INC.
    • 12.2.12 SAGA DIAGNOSTICS
    • 12.2.13 MESO SCALE DIAGNOSTICS, LLC.
    • 12.2.14 CREATIVE BIOLABS

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS